TRP_1170x120_3-8-19

Copaxone

Sandoz releases Copaxone generic

Sandoz releases Copaxone generic

HOLZKIRCHEN, Germany — Following Food and Drug Administration final approval, Sandoz has launched of Glatopa 40 mg/ml (glatiramer acetate injection), a multiple sclerosis medication. The Novartis division said Tuesday that Glatopa 40 mg/ml, manufactured in the United States, was developed under a collaboration pact with Momenta Pharmaceuticals Inc. The product is a fully substitutable generic version of

Pfizer to buy U.S. rights for potential MS generic drug

Pfizer to buy U.S. rights for potential MS generic drug

NEW YORK — Pfizer Inc. has entered into an agreement with Synthon to acquire the exclusive U.S. commercialization rights for glatiramer acetate, a potential generic version of Teva Pharmaceuticals’ Copaxone for the treatment of relapsing remitting multiple sclerosis (RRMS). Pfizer said Monday that under the agreement, it will have exclusive rights to commercialize both dosage

Sandoz releases MS drug Glatopa in U.S.

HOLZKIRCHEN, Germany — Sandoz has begun shipment of Glatopa, a one-time daily treatment for multiple sclerosis (MS), in the United States. The Novartis subsidiary said Thursday that the product (glatiramer acetate injection, 20 mg/ml) is the first generic version of Copaxone 20 mg, from Teva Pharmaceuticals. Developed in collaboration with Momenta and made in the

Sandoz cleared to market Copaxone generic

HOLZKIRCHEN, Germany — Sandoz has received Food and Drug Administration approval for Glatopa, a treatment for multiple sclerosis (MS). The Novartis subsidiary said Thursday that its product is the first generic version of Teva’s Copaxone (glatiramer acetate injection) 20 mg/ml once-daily MS therapy. Glatopa, developed in collaboration with Momenta and made entirely in the United